Marizyme, Inc. (MRZM)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 18.56 Million USD | 282.19% |
| 2022 | 4.85 Million USD | 519.64% |
| 2021 | -1.15 Million USD | 26.95% |
| 2020 | -1.58 Million USD | -1760935.56% |
| 2019 | -90.00 USD | 13.46% |
| 2018 | -104.00 USD | 99.81% |
| 2017 | -54 Thousand USD | -171.69% |
| 2016 | 75.33 Thousand USD | -92.92% |
| 2015 | 1.06 Million USD | 4278.75% |
| 2014 | 24.31 Thousand USD | -95.84% |
| 2013 | 584.91 Thousand USD | -77.23% |
| 2012 | 2.56 Million USD | 141.03% |
| 2011 | -6.25 Million USD | -1234607.69% |
| 2010 | -507.00 USD | 46.29% |
| 2009 | -944.00 USD | 31.2% |
| 2008 | -1372.00 USD | -228.23% |
| 2007 | -418.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 23.55 Million USD | 26.83% |
| 2024 Q2 | 20.44 Million USD | -13.17% |
| 2023 FY | 18.56 Million USD | 282.19% |
| 2023 Q2 | 14.14 Million USD | 86.62% |
| 2023 Q4 | 18.56 Million USD | -12.08% |
| 2023 Q3 | 21.12 Million USD | 49.3% |
| 2023 Q1 | 7.58 Million USD | 56.02% |
| 2022 Q1 | -1.47 Million USD | -27.13% |
| 2022 Q2 | 706.51 Thousand USD | 148.0% |
| 2022 Q4 | 4.85 Million USD | 115.31% |
| 2022 FY | 4.85 Million USD | 519.64% |
| 2022 Q3 | 2.25 Million USD | 219.39% |
| 2021 Q4 | -1.15 Million USD | -157.8% |
| 2021 FY | -1.15 Million USD | 26.95% |
| 2021 Q2 | 1.51 Million USD | 237.79% |
| 2021 Q1 | 447.3 Thousand USD | 128.22% |
| 2021 Q3 | 2 Million USD | 32.58% |
| 2020 Q4 | -1.58 Million USD | 69.5% |
| 2020 FY | -1.58 Million USD | -1760935.56% |
| 2020 Q2 | -3454.00 USD | -5656.67% |
| 2020 Q1 | -60.00 USD | 33.33% |
| 2020 Q3 | -5.19 Million USD | -150349.22% |
| 2019 FY | -90.00 USD | 13.46% |
| 2019 Q1 | -191.00 USD | -83.65% |
| 2019 Q3 | - USD | 100.0% |
| 2019 Q2 | -4382.00 USD | -2194.24% |
| 2019 Q4 | -90.00 USD | 0.0% |
| 2018 Q3 | 72.28 Thousand USD | 1347.07% |
| 2018 Q1 | 51.6 Thousand USD | 195.56% |
| 2018 FY | -104.00 USD | 99.81% |
| 2018 Q2 | -5796.00 USD | -111.23% |
| 2018 Q4 | -104.00 USD | -100.14% |
| 2017 Q4 | -54 Thousand USD | -35.01% |
| 2017 FY | -54 Thousand USD | -171.69% |
| 2017 Q3 | -40 Thousand USD | -33.33% |
| 2017 Q2 | -30 Thousand USD | -352.46% |
| 2017 Q1 | 11.88 Thousand USD | 0.0% |
| 2016 FY | 75.33 Thousand USD | -92.92% |
| 2015 FY | 1.06 Million USD | 4278.75% |
| 2014 FY | 24.31 Thousand USD | -95.84% |
| 2013 FY | 584.91 Thousand USD | -77.23% |
| 2013 Q4 | 584.91 Thousand USD | -89.17% |
| 2013 Q3 | 5.4 Million USD | 81.74% |
| 2013 Q2 | 2.97 Million USD | 41.94% |
| 2013 Q1 | 2.09 Million USD | -18.44% |
| 2012 FY | 2.56 Million USD | 141.03% |
| 2012 Q4 | 2.56 Million USD | -14.97% |
| 2012 Q3 | 3.02 Million USD | 18.89% |
| 2012 Q2 | 2.54 Million USD | -24.43% |
| 2012 Q1 | 3.36 Million USD | 114.06% |
| 2011 FY | -6.25 Million USD | -1234607.69% |
| 2011 Q4 | 1.57 Million USD | -23.82% |
| 2011 Q3 | 2.06 Million USD | 139.29% |
| 2011 Q2 | -5.24 Million USD | 16.18% |
| 2011 Q1 | -6.25 Million USD | -42817.65% |
| 2010 Q1 | 4.85 Million USD | 2492147.69% |
| 2010 Q2 | - USD | -100.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | -14.58 Thousand USD | 0.0% |
| 2010 FY | -507.00 USD | 46.29% |
| 2009 FY | -944.00 USD | 31.2% |
| 2009 Q4 | -195.00 USD | -100.07% |
| 2009 Q3 | 299.59 Thousand USD | 61492.42% |
| 2009 Q2 | -488.00 USD | 48.31% |
| 2009 Q1 | -944.00 USD | -117.51% |
| 2008 Q1 | -1372.00 USD | -27.51% |
| 2008 Q2 | 3458.00 USD | 352.04% |
| 2008 Q4 | -434.00 USD | 90.18% |
| 2008 FY | -1372.00 USD | -228.23% |
| 2008 Q3 | -4418.00 USD | -227.76% |
| 2007 Q2 | -39.63 Thousand USD | 0.0% |
| 2007 Q3 | -31.94 Thousand USD | 19.4% |
| 2007 Q4 | -1076.00 USD | 96.63% |
| 2007 FY | -418.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 1417583.13% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -228.75% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 56.607% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 7538.919% |
| Rebus Holdings, Inc. | 305 Thousand USD | -5988.206% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 394.535% |
| Qrons Inc. | 351.42 Thousand USD | -5183.894% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -2883.628% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 57.248% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 91088.97% |
| Skye Bioscience, Inc. | -5.72 Million USD | 424.555% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -17.801% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -350.921% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -4520.897% |
| SQZ Biotechnologies Company | -36.23 Million USD | 151.242% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -728.149% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -1902.73% |
| Mesoblast Limited | 55.85 Million USD | 66.757% |
| Genus plc | 190.6 Million USD | 90.258% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -730.52% |
| Pharming Group N.V. | 109.8 Million USD | 83.089% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -2058.585% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -1429.715% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -2630.74% |
| ContraFect Corporation | -6.02 Million USD | 408.149% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -13691.716% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -1507.111% |
| IMV Inc. | 7.67 Million USD | -142.083% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -237.502% |
| MultiCell Technologies, Inc. | 90.04 USD | -20622988.627% |
| ONE Bio Corp. | 9.04 Million USD | -105.409% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 2629.916% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -43.434% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -1257.414% |
| Q BioMed Inc. | 4.06 Million USD | -357.364% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 39.226% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -1742.685% |
| Biomind Labs Inc. | 711.4 Thousand USD | -2510.202% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 69.331% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -828.734% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -44.996% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -5062.222% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -13182.187% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -93366.699% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -743.287% |
| GB Sciences, Inc. | 1.74 Million USD | -962.717% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 10203.505% |
| HST Global, Inc. | 96.79 Thousand USD | -19084.268% |
| CSL Limited | 10.52 Billion USD | 99.824% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -8904.606% |
| Halberd Corporation | 144.72 Thousand USD | -12730.915% |
| Enzolytics Inc. | 981.65 Thousand USD | -1791.602% |
| Agentix Corp. | 37.63 Thousand USD | -49245.032% |
| Resverlogix Corp. | 6.45 Million USD | -187.847% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 2858.778% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.915% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 139.498% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -162.609% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -585.554% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 310.059% |
| AVAX Technologies, Inc. | -5.9 Million USD | 414.558% |
| Zenith Capital Corp. | 10.06 Thousand USD | -184409.43% |
| Genscript Biotech Corporation | -1.06 Billion USD | 101.75% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -9164.503% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -678.238% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -11187.546% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 101470.395% |
| Kadimastem Ltd | -253.1 Thousand USD | 7436.579% |
| Helix BioMedix, Inc. | -2.57 Million USD | 822.521% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 8.419% |
| BioStem Technologies, Inc. | 4.47 Million USD | -315.228% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -9126.663% |
| LadRx Corporation | -2.03 Million USD | 1011.825% |
| Cell Source, Inc. | 9.23 Million USD | -101.138% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -2823.488% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -2823.488% |
| NovAccess Global Inc. | 2.17 Million USD | -752.391% |
| Affymax, Inc. | -5.59 Million USD | 431.768% |
| Itoco Inc. | 228.3 Thousand USD | -8033.431% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -13554.802% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -274.602% |
| Mobile Lads Corp. | 484.23 Thousand USD | -3734.738% |
| CytoDyn Inc. | 20.26 Million USD | 8.355% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 2870119.938% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 200449.027% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -140.968% |
| SYBLEU INC | 473.71 Thousand USD | -3819.882% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -316.624% |
| International Stem Cell Corporation | 2.59 Million USD | -616.951% |
| Bioxytran, Inc. | 1.89 Million USD | -877.876% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -29651.861% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -751.439% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -440.741% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -117.105% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -2303.425% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 1585.522% |
| Neutra Corp. | 52.18 Thousand USD | -35481.714% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 846.044% |
| PureTech Health plc | -167.19 Million USD | 111.106% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 7682.043% |
| IXICO plc | -4.44 Million USD | 517.79% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -40.472% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 66.146% |
| CSL Limited | 10.52 Billion USD | 99.824% |
| Cellectis S.A. | -43.81 Million USD | 142.377% |